Gefitinib with Chemotherapy does not Significantly Improve Progression-Free Survival Lung Cancer

At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation of gefitinib with chemotherapy versus chemotherapy alone provided no significant improvement in progression-free survival in patients with EGFR mutation-positive lung cancer who previously failed to respond to first-line gefitinib.

Year of Production:
Running Time:
Color/Sound:

2014
05:05
Color/Sound

Comments are closed.